RCKT Stock Analysis: Buy, Sell, or Hold?
RCKT - Rocket Pharmaceuticals, Inc. Common Stock
$2.75
0.09 (3.38%)
▲
5d:
+0.0%
30d:
-23.61%
90d:
-41.86%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RCKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RCKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RCKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RCKT is currently trading at $2.75, which is considered oversold relative to its 30-day fair value range of $2.77 to $3.49.
Technical Outlook: Technically, RCKT is in a uptrend. Immediate support is located at $2.53, while resistance sits at $3.15. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: RCKT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.39 (+241.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RCKT is in a uptrend. Immediate support is located at $2.53, while resistance sits at $3.15. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: RCKT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.39 (+241.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.77 -
$3.49
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 241.3% below Wall St target ($9.39)
Trading Range Analysis
30-Day Trading Range
$2.77 -
$3.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.53
Resistance Level
$3.15
Current Trend
Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.44
Wall Street Target
$9.39
(+241.3%)
Share & Embed Analysis
Last updated: June 15, 2026 1:50 AM ET
Data refreshes hourly during market hours. Next update: 2:50 AM
Data refreshes hourly during market hours. Next update: 2:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
John Militello
SELL
1157 shares
2026-02-18
Gaurav Shah
SELL
12279 shares
2026-02-13
John Militello
SELL
3726 shares
2026-02-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 62 BUY |
